Caplin Point Laboratories Ltd. has been recognized yet again in Forbes Asia's 200 Best under a Billion list for the year 2024, a compilation that underscores companies' sustained and robust performance across critical benchmarks. 

Carefully selected from a substantial pool of more than 20,000 publicly traded companies across the Asia-Pacific region, 200 enterprises with annual sales under $1 billion are chosen based on qualitative and quantitative metrics. The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity.

Commenting on the achievement, C. C. Paarthipan, Chairman said, “Caplin Point Laboratories Ltd's inclusion in Forbes Asia's '200 Best Under a Billion' list for the seventh time underscores our relentless pursuit of excellence and financial discipline. This recognition, a rare achievement for an Indian pharmaceutical company, reflects our ongoing efforts to strengthen cash flows and ensure consistent profitability. We are committed to upholding the highest standards in every aspect of our business, ensuring sustained growth and value creation for our stakeholders.”

Caplin Point Laboratories Ltd. is a fast-growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa.